The Role of the Complement Inhibitor CD59 on Breast Cancer Cells.

Abstract

It is proposed that reversing the effects of CD59, a tumor cell expressed complement inhibitor, will allow effective immune-mediated clearance of tumor cells and improve prospects for successful immunotherapy. This study investigates the role of complement and CD59 in tumorigenesis. CD59 function is species selective, and an appropriate rat model utilizing human tumor cells expressing rat CD59 will be developed. We have: (1) Confirmed that CD59 is important in protecting human tumor cells from complement-mediated lysis. (2) Identified several anti-breast tumor-specific antibodies that target active complement to breast cancer cell lines. (3) Determined growth conditions for breast cancer cell lines in nude rats, and (4) Further defined the species selective active site of human CD59 for future design of CD59-inhibitory peptides.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 1998
Accession Number
ADA359635

Entities

People

  • Stephen Tomlinson

Organizations

  • NYU Langone Health

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Biomedical Research
  • Blood
  • Blood Proteins
  • Breast Cancer
  • Cell Line
  • Cell Membrane
  • Cells
  • Chemistry
  • Immune Serums
  • Materials
  • Molecules
  • Neoplasms
  • New York
  • Proteins
  • Standards
  • Tumor Cell Line

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology
  • Molecular Biology and Genetics
  • Molecular Genetics

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech